StockData
TG Therapeutics, Inc. logo

TG Therapeutics, Inc. (TGTX) bonds

TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 9/303% above fair value
$66.12+3.41 (+5.44%)

Close on Nov 18, 2026Market cap $10.12BP/E 24.1Yield –

Debt

Borrowings on the balance sheet, Jun 30, 2026

Total debt
$745.39M
Long-term debt
Net debt
$262.81M
After $482.58M of cash
Implied interest rate
10.91%
FY2025 interest ÷ average debt
Interest coverage
4.6×
FY2025 operating income ÷ interest

Total debt by fiscal year

Long-term plus current debt, USD

When the debt comes due

Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2023

From the debt maturity table in the annual report (filing). “Later” is everything due after year five.

Notes and loans outstanding

As tagged in TG Therapeutics's 10-Q for the period ended Jun 30, 2026

IssueCouponMaturesAmount issuedCarrying value
The2026 Term Loan2.00%2026$750.00M–
Initial Term Loan––$250.00M–
The First Amendment Term Loan––$250.00M$250.00M

Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.

See a number that looks wrong?